As of 2:31 PM on the 2nd, Pamisell is trading at 20,100 KRW, up 7.77% from the previous day. This is a 9.87% decrease compared to June 12. Pamisell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Over the past five days, individual investors have sold a net 142,407 shares, while foreigners and institutions have bought a net 48,254 shares and 6,649 shares, respectively.
On June 22, Pamisell was a market topic for its "strength due to recommendation of Remdesivir administration."
※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
